Previous 10 |
Unicycive Therapeutics Announces Third Quarter 2021 Financial Results Expect to receive confirmatory guidance on Renazorb regulatory pathway from the U.S. Food and Drug Administration in Q4 2021 PR Newswire LOS ALTOS, Calif. , Nov. 11, 2021 /PRNewswire/ --...
Unicycive Therapeutics Appoints Douglas Jermasek As Executive Vice President, Corporate Strategy PR Newswire LOS ALTOS, Calif. , Oct. 26, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies...
The following slide deck was published by Unicycive Therapeutics, Inc. in conjunction with this event. For further details see: Unicycive Therapeutics (UNCY) Investor Presentation - Slideshow
Unicycive Therapeutics to be Added to Russell Microcap® Index PR Newswire LOS ALTOS, Calif. , Sept. 15, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidne...
Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire LOS ALTOS, Calif. , Sept. 7, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing the...
Unicycive Therapeutics Announces Second Quarter 2021 Financial Results Completed initial public offering in July 2021 with gross proceeds of $25 million Planned meeting with the U.S. FDA in Q4 2021 to align on Renazorb program PR Newswire LOS ALTOS, Calif. , ...
Unicycive Therapeutics Inc. (NASDAQ:UNCY) traded today at a new 52-week low of $2.68. So far today approximately 521,000 shares have been exchanged, as compared to an average 30-day volume of 0,000 shares. Based on a current price of $2.78, Unicycive Therapeutics Inc. is currently 7.3% a...
News, Short Squeeze, Breakout and More Instantly...
Unicycive Therapeutics Inc. Company Name:
UNCY Stock Symbol:
NASDAQ Market:
Unicycive Therapeutics Inc. Website:
LOS ALTOS, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the issuance of U.S. Pate...
LOS ALTOS, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief E...
– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a...